367 related articles for article (PubMed ID: 24723457)
21. Refractory anemia with ring sideroblasts and RARS with thrombocytosis.
Patnaik MM; Tefferi A
Am J Hematol; 2015 Jun; 90(6):549-59. PubMed ID: 25899435
[TBL] [Abstract][Full Text] [Related]
22. Clinical, biological, and prognostic implications of SF3B1 co-occurrence mutations in very low/low- and intermediate-risk MDS patients.
Janusz K; Izquierdo MM; Cadenas FL; Ramos F; Sánchez JMH; Lumbreras E; Robledo C; Del Real JS; Caballero JC; Collado R; Bernal T; Pedro C; Insunza A; de Paz R; Xicoy B; Salido E; García JS; Mínguez SS; García CM; Muñoz AMS; Barba MS; Rivas JMH; Abáigar M; Campelo MD
Ann Hematol; 2021 Aug; 100(8):1995-2004. PubMed ID: 33409621
[TBL] [Abstract][Full Text] [Related]
23. Depletion of Sf3b1 impairs proliferative capacity of hematopoietic stem cells but is not sufficient to induce myelodysplasia.
Wang C; Sashida G; Saraya A; Ishiga R; Koide S; Oshima M; Isono K; Koseki H; Iwama A
Blood; 2014 May; 123(21):3336-43. PubMed ID: 24735968
[TBL] [Abstract][Full Text] [Related]
24. Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutations.
Jeromin S; Haferlach T; Weissmann S; Meggendorfer M; Eder C; Nadarajah N; Alpermann T; Kohlmann A; Kern W; Haferlach C; Schnittger S
Haematologica; 2015 Apr; 100(4):e125-7. PubMed ID: 25527566
[No Abstract] [Full Text] [Related]
25.
Mortera-Blanco T; Dimitriou M; Woll PS; Karimi M; Elvarsdottir E; Conte S; Tobiasson M; Jansson M; Douagi I; Moarii M; Saft L; Papaemmanuil E; Jacobsen SEW; Hellström-Lindberg E
Blood; 2017 Aug; 130(7):881-890. PubMed ID: 28634182
[TBL] [Abstract][Full Text] [Related]
26. IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution.
Lin CC; Hou HA; Chou WC; Kuo YY; Liu CY; Chen CY; Lai YJ; Tseng MH; Huang CF; Chiang YC; Lee FY; Liu MC; Liu CW; Tang JL; Yao M; Huang SY; Ko BS; Wu SJ; Tsay W; Chen YC; Tien HF
Am J Hematol; 2014 Feb; 89(2):137-44. PubMed ID: 24115220
[TBL] [Abstract][Full Text] [Related]
27. Clinical Outcomes With Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium Analysis.
Migdady Y; Barnard J; Al Ali N; Steensma DP; DeZern A; Roboz G; Garcia-Manero G; Sekeres MA; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):528-532. PubMed ID: 29937400
[TBL] [Abstract][Full Text] [Related]
28. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts.
Papaemmanuil E; Cazzola M; Boultwood J; Malcovati L; Vyas P; Bowen D; Pellagatti A; Wainscoat JS; Hellstrom-Lindberg E; Gambacorti-Passerini C; Godfrey AL; Rapado I; Cvejic A; Rance R; McGee C; Ellis P; Mudie LJ; Stephens PJ; McLaren S; Massie CE; Tarpey PS; Varela I; Nik-Zainal S; Davies HR; Shlien A; Jones D; Raine K; Hinton J; Butler AP; Teague JW; Baxter EJ; Score J; Galli A; Della Porta MG; Travaglino E; Groves M; Tauro S; Munshi NC; Anderson KC; El-Naggar A; Fischer A; Mustonen V; Warren AJ; Cross NC; Green AR; Futreal PA; Stratton MR; Campbell PJ;
N Engl J Med; 2011 Oct; 365(15):1384-95. PubMed ID: 21995386
[TBL] [Abstract][Full Text] [Related]
29. SF3B1 Mutation but Not Ring Sideroblasts Identifies a Specific Group of Myelodysplastic Syndrome-Refractory Cytopenia With Multilineage Dysplasia.
Xiong B; Xue M; Yu Y; Wu S; Zuo X
Clin Lymphoma Myeloma Leuk; 2020 May; 20(5):329-339.e3. PubMed ID: 32037286
[TBL] [Abstract][Full Text] [Related]
30. The Frequency of SF3B1 Mutations in Thai Patients with Myelodysplastic Syndrome.
Rujirachaivej P; Siriboonpiputtana T; Rerkamnuaychoke B; Magmuang S; Chareonsirisuthigul T; Boonsakan P; Petvises S; Sirirat T; Niparuck P; Chuncharunee S
Asian Pac J Cancer Prev; 2018 Jul; 19(7):1825-1831. PubMed ID: 30049194
[TBL] [Abstract][Full Text] [Related]
31. Alteration of SF3B1 and SRSF2 Genes in Myelodysplastic Syndromes Patients in Upper Northern Thailand.
Yimpak P; Tantiworawit A; Rattanathammethee T; Angsuchawan S; Laowatthanapong S; Tasuya W; Bumroongkit K
Asian Pac J Cancer Prev; 2019 Apr; 20(4):1215-1221. PubMed ID: 31030497
[TBL] [Abstract][Full Text] [Related]
32. [Clinical features of SF3B1 mutation in patients with myelodysplastic syndrome with excess blasts].
He F; Li T; Li YF; Tang P; Sang LN; Huang YM; Sun L; Liu L
Zhonghua Nei Ke Za Zhi; 2023 Jun; 62(6):681-687. PubMed ID: 37263951
[No Abstract] [Full Text] [Related]
33. Prognostic value and clinical feature of SF3B1 mutations in myelodysplastic syndromes: A meta-analysis.
Tang Y; Miao M; Han S; Qi J; Wang H; Ruan C; Wu D; Han Y
Crit Rev Oncol Hematol; 2019 Jan; 133():74-83. PubMed ID: 30661660
[TBL] [Abstract][Full Text] [Related]
34. Aberrant splicing of genes involved in haemoglobin synthesis and impaired terminal erythroid maturation in SF3B1 mutated refractory anaemia with ring sideroblasts.
Conte S; Katayama S; Vesterlund L; Karimi M; Dimitriou M; Jansson M; Mortera-Blanco T; Unneberg P; Papaemmanuil E; Sander B; Skoog T; Campbell P; Walfridsson J; Kere J; Hellström-Lindberg E
Br J Haematol; 2015 Nov; 171(4):478-90. PubMed ID: 26255870
[TBL] [Abstract][Full Text] [Related]
35. Genetic landscape of recurrent ASXL1, U2AF1, SF3B1, SRSF2, and EZH2 mutations in 304 Chinese patients with myelodysplastic syndromes.
Wu L; Song L; Xu L; Chang C; Xu F; Wu D; He Q; Su J; Zhou L; Xiao C; Zhang Z; Zhao Y; Chen S; Li X
Tumour Biol; 2016 Apr; 37(4):4633-40. PubMed ID: 26508027
[TBL] [Abstract][Full Text] [Related]
36. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis.
Makishima H; Visconte V; Sakaguchi H; Jankowska AM; Abu Kar S; Jerez A; Przychodzen B; Bupathi M; Guinta K; Afable MG; Sekeres MA; Padgett RA; Tiu RV; Maciejewski JP
Blood; 2012 Apr; 119(14):3203-10. PubMed ID: 22323480
[TBL] [Abstract][Full Text] [Related]
37. Negative impact on clinical outcome of the mutational co-occurrence of SF3B1 and DNMT3A in refractory anemia with ring sideroblasts (RARS).
Martín I; Such E; Navarro B; Vicente A; López-Pavía M; Ibáñez M; Tormo M; Villamón E; Gómez-Seguí I; Luna I; Oltra S; Pedrola L; Sanz MA; Cervera J; Sanz G
Leuk Lymphoma; 2017 Jul; 58(7):1686-1693. PubMed ID: 27771989
[TBL] [Abstract][Full Text] [Related]
38. Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1.
Ambaglio I; Malcovati L; Papaemmanuil E; Laarakkers CM; Della Porta MG; Gallì A; Da Vià MC; Bono E; Ubezio M; Travaglino E; Albertini R; Campbell PJ; Swinkels DW; Cazzola M
Haematologica; 2013 Mar; 98(3):420-3. PubMed ID: 23300182
[TBL] [Abstract][Full Text] [Related]
39. Splicing factor 3b subunit 1 (Sf3b1) haploinsufficient mice display features of low risk Myelodysplastic syndromes with ring sideroblasts.
Visconte V; Tabarroki A; Zhang L; Parker Y; Hasrouni E; Mahfouz R; Isono K; Koseki H; Sekeres MA; Saunthararajah Y; Barnard J; Lindner D; Rogers HJ; Tiu RV
J Hematol Oncol; 2014 Dec; 7():89. PubMed ID: 25481243
[TBL] [Abstract][Full Text] [Related]
40. Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes.
Damm F; Kosmider O; Gelsi-Boyer V; Renneville A; Carbuccia N; Hidalgo-Curtis C; Della Valle V; Couronné L; Scourzic L; Chesnais V; Guerci-Bresler A; Slama B; Beyne-Rauzy O; Schmidt-Tanguy A; Stamatoullas-Bastard A; Dreyfus F; Prébet T; de Botton S; Vey N; Morgan MA; Cross NC; Preudhomme C; Birnbaum D; Bernard OA; Fontenay M;
Blood; 2012 Apr; 119(14):3211-8. PubMed ID: 22343920
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
